Research Topics
Species | Kevan C HeroldSummaryAffiliation: Columbia University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitusKevan C Herold
Naomi Berrie Diabetes Center and the Department of Medicine, Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York 10032, USA
N Engl J Med 346:1692-8. 2002..Preclinical studies suggested that a monoclonal antibody against CD3 could reverse hyperglycemia at presentation and induce tolerance to recurrent disease...- Treatment of Type 1 diabetes with anti-CD3 monoclonal antibody: induction of immune regulation?Kevan C Herold
Department of Medicine, the Naomi Berrie Diabetes Center, and the Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York, NY, USA
Immunol Res 28:141-50. 2003..The induction of cells with a regulatory phenotype may account for the ability of anti-CD3 MAb to induce immune regulation... - Treatment of type 1 diabetes with anti-CD3 monoclonal antibodyMariela Glandt
Division of Endocrinology and the Naomi Berrie Diabetes Center, College of Physicians and Surgeons, Columbia University, New York, NY and the Pacific Northwest Research Institute, Seattle, WA
Rev Endocr Metab Disord 4:361-8. 2003 
Achieving antigen-specific immune regulationKevan C Herold
Naomi Berrie Diabetes Center, Division of Endocrinology and Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
J Clin Invest 113:346-9. 2004..The antigen-specific response characterized by release of a regulatory cytokine suggests a mechanism for the control of autoimmunity that is initiated at the time of antigen presentation...- Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing TregsDamien Bresson
Department of Developmental Immunology 3, La Jolla Institute for Allergy and Immunology, San Diego, California 92121, USA
J Clin Invest 116:1371-81. 2006..Since Tregs act site-specifically, this strategy should also be expected to reduce the potential for systemic side effects... - Achieving antigen-specific tolerance in diabetes: regulating specificallyWei Chen
Naomi Berrie Diabetes Center and the Division of Endocrinology, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
Int Rev Immunol 24:287-305. 2005.... - Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala)Kevan C Herold
Naomi Berrie Diabetes Center, Department of Medicine and Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
J Clin Invest 111:409-18. 2003..It leads to the generation of T cells that might inhibit the autoimmune response and may be involved in the beneficial effect on beta cell destruction in Type 1 diabetes... - A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetesKevan C Herold
Associate Professor of Medicine, Columbia University, PH10 105, 630 W 168th St, New York, NY 10032, USA
Diabetes 54:1763-9. 2005.... - Treatment of type 1 diabetes mellitus to preserve insulin secretionKevan C Herold
Division of Endocrinology, Department of Medicine, Naomi Berrie Diabetes Center, College of Physicians and Surgeons, Columbia University, 1150 St. Nicholas Avenue, New York, NY 10032, USA
Endocrinol Metab Clin North Am 33:93-111, ix. 2004 - Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1Jay M Sosenko
Division of Endocrinology, University of Miami, P O Box 016960 D110, Miami, FL 33101, USA
Diabetes Care 30:38-42. 2007.... - TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ TregsBrygida Bisikirska
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
J Clin Invest 115:2904-13. 2005..Foxp3 was also induced on CD8+ T cells in patients during mAb treatment, which suggests a potential mechanism of the anti-CD3 mAb immune modulatory effects involving induction of a subset of regulatory CD8+ T cells... - Use of anti-CD3 monoclonal antibody to induce immune regulation in type 1 diabetesBrygida C Bisikirska
Department of Medicine, PH-10-105, 630 W. 168th Street, New York, NY 10032, USA
Ann N Y Acad Sci 1037:1-9. 2004..These initial studies have shown clinical efficacy of treatment with anti-CD3 mAb and suggest a novel mechanism that may account for the lasting effects of treatment... - Remission of type 1 diabetes after anti-CD3 antibody treatment and transplantation of embryonic pancreatic precursorsSalma Begum
Department of Genetics and Development, HHSC 1402, Columbia University, New York, New York 10032, USA
Endocrinology 150:4512-20. 2009.... - Insulin secretion in type 1 diabetesChynna Steele
Department of Medicine, Division of Endocrinology, and the Naomi Berrie Diabetes Center, College of Physicians and Surgeons, Columbia University, New York, New York, USA
Diabetes 53:426-33. 2004.... - Effects of controlled-release alpha lipoic acid in lean, nondiabetic patients with polycystic ovary syndromeUmesh Masharani
Department of Medicine, University of California, San Francisco, Diabetes Center, San Francisco, California 94143, USA
J Diabetes Sci Technol 4:359-64. 2010..The purpose of this study was to determine whether a preparation of controlled-release alpha lipoic acid (CRLA) influences features of the polycystic ovary syndrome (PCOS)... - Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1Jay M Sosenko
Division of Endocrinology, University of Miami, PO Box 016960 D110, Miami, FL 33101, USA
Diabetes Care 29:643-9. 2006..The goal of this study was to utilize data from the Diabetes Prevention Trial-Type 1 (DPT-1) to obtain a picture of the metabolic progression to type 1 diabetes over a period of approximately 2.5 years before its diagnosis... - Autoimmunity and beta cell regeneration in mouse and human type 1 diabetes: the peace is not enoughVitaly Ablamunits
Section of Immunobiology, Department of Medicine, Yale University School of Medicine, New Haven, CT 06520, USA
Ann N Y Acad Sci 1103:19-32. 2007..Additional therapeutic modalities capable of stimulating beta cell regeneration in the absence of active autoimmune destruction are urgently needed... - Drug insight: New immunomodulatory therapies in type 1 diabetesSimona Cernea
Columbia University, New York, NY, USA
Nat Clin Pract Endocrinol Metab 2:89-98. 2006..Ultimately, preservation and even improvement in beta-cell mass is the goal of therapy. The means needed to achieve this will depend on the timing and mechanisms of the immune intervention and might require combinations of agents... - Natural history of beta-cell function in type 1 diabetesNicole A Sherry
Naomie Berrie Diabetes Center and Department of Pediatrics, College of Physicians and Surgeons, Columbia University, 1150 St. Nicholas Ave, New York, New York 10032, USA
Diabetes 54:S32-9. 2005..Understanding the modifiers and predictors of beta-cell function would allow targeting immunological approaches to those individuals most likely to benefit from therapy... - Regulatory T cells and type 1 diabetesBrygida C Bisikirska
Division of Endocrinology, Naomi Berrie Diabetes Center, Department of Medicine, College of Physicians and Surgeons, Columbia University, Room 10-105, 630 W. 168th Street, New York, NY 10032, USA
Curr Diab Rep 5:104-9. 2005..These cells may be expanded by immune therapy, suggesting the possible development of adoptive immune therapy to transfer regulation with the cells... - Treatment of type 1 diabetes with anti-T-cell agents: from T-cell depletion to T-cell regulationMariela Glandt
Department of Medicine, College of Physicians and Surgeons, Columbia University, 1150 St. Nicholas Avenue, New York, NY 10032, USA
Curr Diab Rep 4:291-7. 2004..Data now suggest that efficacy and duration of the effects of anti-T-cell drugs can be enhanced when the agents provoke immune modulation rather than depletion of effector cells... - A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain geneMarie King
Department of Medicine, University of Massachusetts Medical School, 373 Plantation Street, Worcester, MA 01655, USA
Clin Immunol 126:303-14. 2008..These data suggest that humanized NOD-scid Il2rgamma(null) mice may represent an important surrogate for investigating in vivo mechanisms of human islet allograft rejection... - Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end productsYali Chen
Naomi Berrie Diabetes Center, Division of Endocrinology, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
J Immunol 173:1399-405. 2004..5. We conclude that RAGE/ligand interactions are involved in the differentiation of T cells to a mature pathogenic phenotype during the late stages of the development of diabetes... - Immunotherapy of type 1 diabetes: where are we and where should we be going?Xunrong Luo
Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
Immunity 32:488-99. 2010.... - C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001Jerry P Palmer
Department of Medicine, University of Washington, and DVA Puget Sound Health Care System, Seattle, Washington 98108, USA
Diabetes 53:250-64. 2004..The development of therapies for addressing this important unmet clinical need will be facilitated by trials that are carefully designed with beta-cell function as determined by C-peptide measurement as the primary efficacy outcome... 
Functional human to mouse adipose tissue xenotransplantationVitaly Ablamunits
Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA
J Endocrinol 212:41-7. 2012..Transfer of 2×10(7) human mononuclear cells to reject WAT as an allograft was ineffective and resulted only in some reduction of circulating leptin and a limited damage to the WAT grafts followed by the loss of human leukocytes...- Islet transplantation for type 1 diabetes--where should we go?Piotr Witkowski
Columbia University, New York, NY, USA
Nat Clin Pract Endocrinol Metab 3:2-3. 2007 - RAGE: a journey from the complications of diabetes to disorders of the nervous system - striking a fine balance between injury and repairLing Ling Rong
Department of Surgery, Columbia University Medical Center, NY 10032, USA
Restor Neurol Neurosci 23:355-65. 2005..Experimental evidence supports the premise that RAGE bears both homeostatic and injurious properties in the nervous system, thereby highlighting "yin/yang" features of this receptor and its ligand families... - Influence of gender on the relationship between insulin sensitivity, adiposity, and plasma lipids in lean nondiabetic subjectsUmesh Masharani
Division of Endocrinology and Metabolism, Department of Medicine, University of California San Francisco, San Francisco, CA 94115, USA
Metabolism 58:1602-8. 2009..These results both highlight sex differences in the associations between insulin resistance, regional adipose stores, and lipids values and emphasize the importance of adipose stores on the development of an individual's lipid profile... - Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cellsNicole A Sherry
Department of Immunobiology, Yale University, New Haven, CT 06520, USA
Endocrinology 148:5136-44. 2007..This combinatorial approach may be useful in treatment of patients with new-onset T1DM... - Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 diabetesNicole A Sherry
Section of Immunobiology, Yale University, 300 Cedar St, Room S155B, New Haven, CT 06520, USA
Diabetes 55:3238-45. 2006..Correction of the beta-cell loss in type 1 diabetes will, therefore, require strategies that target both the immunologic and cellular mechanisms that destroy and maintain beta-cell mass... - Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled studyVicki Seyfert-Margolis
Immune Teolerance Network, Bethesda, Maryland, USA
Diabetes 55:2588-94. 2006..They may be useful for assessment of cellular autoimmune responses involved in type 1 diabetes... - A patient with type B insulin resistance syndrome, responsive to immune therapyKathleen A Page
Section of Endocrinology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06520 8020, USA
Nat Clin Pract Endocrinol Metab 3:835-40. 2007..She remained hyperglycemic (blood glucose levels 16.7-27.8 mmol/l), despite intravenous insulin at doses as high as 30,000 U/day... - RAGE ligation affects T cell activation and controls T cell differentiationYali Chen
Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06520, USA
J Immunol 181:4272-8. 2008..We conclude that activation of RAGE on T cells is involved in early events that lead to differentiation of Th1(+) T cells... - Continuous subcutaneous insulin infusion in older patients with type 1 diabetesLeigh Siegel-Czarkowski
Diabetes Care 27:3022-3. 2004 - Pancreatic islets activate portal vein endothelial cells in vitroMagali J Fontaine
Department of Pathology, Medical University of South Carolina, Charleston, South Carolina 29425, USA
Ann Clin Lab Sci 32:352-61. 2002..Neither lymphocyte proliferation nor cytotoxicity could be enhanced in response to enhanced MHC Class I and ICAM-1 expression, which was associated instead with non-specific inflammatory cytokine release... - Prevention of type 1 diabetes: the time has comeJennifer Sherr
Department of Pediatrics, Yale University School of Medicine, New Haven, CT, USA
Nat Clin Pract Endocrinol Metab 4:334-43. 2008..In this Review we discuss risk-stratification techniques and how they are applied, other diagnostic criteria, and outcomes from diabetes-prevention trials...